2 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs

Feb 15, 2011

In a paper published today in PNAS, scientists from the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, reveal new insights into the workings of enzymes from a group of bacteria including Mycobacterium tuberculosis, the bacterium that causes tuberculosis. The new findings present possible new opportunities for developing organism-specific drugs, which target the pathogen but leave other microorganisms, which are beneficial to us, untouched.

Tuberculosis remains one of the largest threats to human health worldwide, and one of the most frequent causes of death in patients. With the increasing emergence of strains of Mycobacterium that are hyper-resistant to drugs, it becomes ever more urgent that novel treatments be developed, and the search for novel strategies for drug development is an important step in this process.

This video is not supported by your browser at this time.
Three snapshots of the 3-D structure of Mycobacterium tuberculosis' enzyme PriA are combined in this video to show the changes the enzyme is capable of undergoing. Credit: EMBL/Felix List

In the current study, Matthias Wilmanns and his group at EMBL identified a multi-tasking enzyme from Mycobacterium tuberculosis that catalyses reactions on two different molecules, or substrates. In most organisms, cells need two specific enzymes, known as HisA and TrpF, in order to produce two essential amino acids – histidine and tryptophan. However, in Mycobacterium tuberculosis, the encoding gene for TrpF is missing, and the two reactions are instead catalysed by a single enzyme, which is able to recognize and bind to two different substrates. This enzyme is known as PriA.

Using the Mycobacterium tuberculosis version of the PriA enzyme as a model, the researchers were able to unravel the hitherto unknown mechanism of bi-substrate specific binding observed in this group of bacteria.

"When we solved the three-dimensional structure of PriA, we found that it has the unique ability to form two different substrate-specific active sites," Wilmanns says: "it can form a reaction-specific active site, or undergo what we call 'substrate-induced metamorphosis' to form a different active site."

To further verify these observations, Wilmanns and colleagues screened 20,000 small molecule compounds, and identified a handful which inhibited both PriA-catalysed reactions but had no effect on TrpF activity.

"We believe that this ability for bi-substrate catalysis in Mycobacterium tuberculosis could be a new opportunity for future drug development," Wilmanns concludes: "This organism-specific reaction process could be exploited, since only the pathogen but none of the other bacteria living in or on humans, many of which are important for our well being, would be targeted."

Explore further: Compound from soil microbe inhibits biofilm formation

Related Stories

Key to TB's 'staying power' unlocked

Feb 20, 2008

The first report of a biomolecular structure resolved using the Oxfordshire Diamond synchrotron is giving vital help in the fight against tuberculosis.

Cancer drug target is promising lead for new TB treatments

Nov 17, 2010

A key enzyme in Mycobacterium tuberculosis that enables the microbe to reproduce rapidly could be a golden target for new drugs against tuberculosis (TB), according to a study published in Microbiology on 17 November. ...

Scientists discover bacteria that can cause bone infections

Oct 17, 2008

Scientists have discovered that a bone infection is caused by a newly described species of bacteria that is related to the tuberculosis pathogen. The discovery may help improve the diagnosis and treatment of similar infections, ...

In India: A search for more effective tuberculosis drugs

Feb 01, 2009

Rajesh Gokhale has created a compound in his lab in India that stops tuberculosis in its tracks. In a test tube, the molecule hits four of the bacterium's crucial metabolic pathways at the same time, weakening and ultimately ...

Recommended for you

How a deadly fungus evades the immune system

1 minute ago

New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most c ...

Compound from soil microbe inhibits biofilm formation

17 hours ago

Researchers have shown that a known antibiotic and antifungal compound produced by a soil microbe can inhibit another species of microbe from forming biofilms—microbial mats that frequently are medically harmful—without ...

Researcher among best in protein modeling contests

20 hours ago

A Purdue University researcher ranks among the best in the world in bioinformatics competitions to predict protein structure, docking and function, making him a triple threat in the world of protein modeling.

Survey of salmonella species in Staten Island Zoo's snakes

21 hours ago

For humans, Salmonella is always bad news. The bacterial pathogen causes paratyphoid fever, gastroenteritis and typhoid. But for snakes, the bacteria aren't always bad news. Certain species of Salmonella are a natural part ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.